ClinicalTrials.gg

Program

Acetaminophen

Also written as “Paracetamol”, “IV Acetaminophen” and “Experimental paracetamol formulation”.

Its studies are mostly in Pain · Pain, Postoperative · Migraine Disorders · Common Cold · Fever, led by 26 companies.

Furthest: phase 4, since Sep 13, 2005123 company-led studies, 1 open or runningNext primary completion: May 17, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson390 open or runningphase 4since Sep 13, 2005Sep 13, 2005none ahead
GlaxoSmithKline240 open or runningphase 4since Feb 18, 2010Jun 2, 2006none ahead
Keenova Therapeutics110 open or runningphase 4since Feb 5, 2016Nov 14, 2006none ahead
Allodynic Therapeutics60 open or runningphase 3since Jun 8, 2017Feb 17, 2017none ahead
Novartis60 open or runningphase 4since Jun 19, 2007Jan 29, 2007none ahead
Sanofi41 open or runningphase 3since Feb 12, 2007Feb 12, 2007May 17, 2027phase 2 · NCT06647407
Sun Pharmaceutical Industries40 open or runningno phasesince Feb 18, 2010Feb 18, 2010none ahead
AFT Pharmaceuticals30 open or runningphase 3since Aug 16, 2011Aug 16, 2011none ahead
Nevakar30 open or runningphase 2since Jul 8, 2019Jul 8, 2019none ahead
Angelini Pharma20 open or runningphase 2since Apr 9, 2015Apr 9, 2015none ahead
Baxter Healthcare20 open or runningphase 3since Nov 29, 2006Nov 29, 2006none ahead
Grünenthal20 open or runningphase 1since Apr 27, 2017Apr 27, 2017none ahead
Hamad Medical20 open or runningphase 4since Dec 12, 2019Jun 21, 2013none ahead
Laboratorios Silanes S.A. de C.V.20 open or runningphase 3since Mar 3, 2025Jun 15, 2022none ahead
sintetica-sa20 open or runningphase 2since Dec 23, 2015Dec 23, 2015none ahead
ascension-health10 open or runningphase 4since Aug 23, 2018Aug 23, 2018none ahead
AstraZeneca10 open or runningphase 1since Aug 24, 2018Aug 24, 2018none ahead
Boehringer Ingelheim10 open or runningphase 3since Jul 7, 2014Jul 7, 2014none ahead
Bristol-Myers Squibb10 open or runningphase 4since Jun 23, 2006Jun 23, 2006none ahead
Eurofarma Laboratorios10 open or runningphase 3since Oct 5, 2021Oct 5, 2021none ahead
HALEON10 open or runningphase 1since Feb 28, 2025Feb 28, 2025none ahead
Intarcia Therapeutics10 open or runningphase 1since Dec 21, 2015Dec 21, 2015none ahead
Par Health10 open or runningphase 1since Apr 1, 2008Apr 1, 2008none ahead
qc-kinetix-llc10 open or runningphase 2since Feb 6, 2023Feb 6, 2023none ahead
Reckitt10 open or runningphase 3since Oct 26, 2010Oct 26, 2010none ahead
rottapharm10 open or runningphase 3since May 9, 2005May 9, 2005none ahead

Also a collaborator on its studies: nevakar-injectables-inc, cross-s-a, cross-research-s-a, premier-research-group-plc, aptuit, mds-pharma-services and pricara-unit-of-ortho-mcneil-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jun 23, 2011.

  1. Jun 23, 2020Phase 2 study in PainJohnson & Johnson · NCT04447040 · 304 enrolled · United States
  2. Jul 27, 2020Phase 2 study in Pain, PostoperativeNevakar · NCT04495283 · 87 enrolled · United States
  3. Oct 5, 2021Eurofarma Laboratorios's first study: phase 3 study in Common ColdNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT05118672 · 567 enrolled · Brazil
  4. Jun 15, 2022Laboratorios Silanes S.A. de C.V.'s first study: phase 1 study in PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT05428306 · 42 enrolled · Mexico
  5. Dec 27, 2022Phase 2 study in Migraine DisordersAllodynic Therapeutics · NCT05685225 · United States
  6. Feb 6, 2023qc-kinetix-llc's first study: phase 2 study in Osteoarthritis, KneeNew to qc-kinetix-llcqc-kinetix-llc · NCT05742763 · United States
  7. Feb 27, 2023Phase 3 study in PainJohnson & Johnson · NCT05761574 · 447 enrolled · United States
  8. Apr 25, 2023Phase 3 study in Orthodontic PainJohnson & Johnson · NCT05845008 · United States
  9. Apr 25, 2023Phase 1 study in Orthodontic PainJohnson & Johnson · NCT05844995 · 24 enrolled · United States
  10. May 11, 2023Phase 3 study in PainJohnson & Johnson · NCT05868122 · 143 enrolled · United States
  11. Jan 30, 2024Phase 2 study in Migraine DisordersAllodynic Therapeutics · NCT06245902 · 92 enrolled · United States
  12. Oct 16, 2024Phase 2 study in Meningococcal ImmunizationSanofi · NCT06647407 · 750 enrolled · Brazil, Czechia, Denmark and more
  13. Feb 28, 2025HALEON's first study: phase 1 study in FeverNew to HALEONHALEON · NCT06855576 · 54 enrolled · Germany
  14. Mar 3, 2025Phase 3 study in ArthralgiaLaboratorios Silanes S.A. de C.V. · NCT06863636 · 231 enrolled · Mexico

Ahead

  1. May 17, 2027Primary completion: phase 2 study in Meningococcal ImmunizationSanofi · NCT06647407

TargetBeta

“Cyclooxygenase inhibitor; Anandamide amidohydrolase inhibitor; Vanilloid receptor opener”ChEMBL 37, by rule

Studies

The newest 60 of 123 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06863636Arthralgia · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Oct 30, 2025231
NCT06855576Fever · Germany1CompletedHALEONApr 17, 202554
NCT06647407Meningococcal Immunization · Brazil, Czechia, Denmark and more2Active, not recruitingSanofiMay 17, 2027750
NCT06245902Migraine Disorders · United States2CompletedAllodynic TherapeuticsFeb 8, 201892
NCT05868122Pain · United States3CompletedJohnson & JohnsonMay 25, 2024143
NCT05845008Orthodontic Pain · United States3WithdrawnJohnson & JohnsonJul 15, 20240
NCT05844995Orthodontic Pain · United States1CompletedJohnson & JohnsonFeb 12, 202424
NCT05761574Pain · United States3CompletedJohnson & JohnsonMay 17, 2024447
NCT05742763Osteoarthritis, Knee · United States2Withdrawnqc-kinetix-llcOct 7, 20240
NCT05685225Migraine Disorders · United States2WithdrawnAllodynic TherapeuticsDec 2, 20250
NCT05428306Pain · Mexico1CompletedLaboratorios Silanes S.A. de C.V.Nov 6, 201842
NCT05118672Common Cold · Brazil3CompletedEurofarma LaboratoriosAug 26, 2025567
NCT04495283Pain, Postoperative · United States2CompletedNevakarNov 12, 202087
NCT04447040Pain · United States2CompletedJohnson & JohnsonApr 9, 2021304
NCT04265456Pain, Postoperative · United States1CompletedNevakarJun 15, 202063
NCT04230252Healthy · Korea, Republic of1CompletedJohnson & JohnsonFeb 10, 202030
NCT04214691Healthy · Korea, Republic of1CompletedJohnson & JohnsonJan 16, 202030
NCT04199572Musculoskeletal Injury · Qatar4CompletedHamad MedicalFeb 21, 2023162
NCT04018612Pain, Postoperative · United States2CompletedNevakarJul 26, 2019110
NCT03879408Pain · United States2CompletedJohnson & JohnsonNov 7, 2019290
NCT03649165Neurofibromatosis 1 · United States1CompletedAstraZenecaOct 21, 201824
NCT03702023Post Electrophysiology Procedure Pain · United States4UNKNOWNascension-healthJun 1, 2020200
NCT03428230Pain, Postoperative · Switzerland2Completedsintetica-saOct 22, 201960
NCT03415243Common Cold · United States1CompletedGlaxoSmithKlineMar 29, 201828
NCT03368664Multiple Sclerosis · France, Italy, Poland and more3TerminatedSanofiMay 4, 202116
NCT03201393Radiculopathy · United States2CompletedAllodynic TherapeuticsJul 26, 201812
NCT03194555Headache · United States2CompletedAllodynic TherapeuticsJul 26, 201812
NCT03185143Migraine With and Without Aura · United States3CompletedAllodynic TherapeuticsMay 7, 201836
NCT03137030Opioid-Related Disorders · United States1WithdrawnGrünenthalJan 20180
NCT03137017Opioid-Related Disorders · United States1WithdrawnGrünenthalNov 20170
NCT03061734Migraine Disorders · United States2CompletedAllodynic TherapeuticsFeb 8, 201892
NCT02974114Pain · United Kingdom4TerminatedGlaxoSmithKlineFeb 6, 201721
NCT02902666Healthy1CompletedAngelini PharmaMay 201646
NCT02848729Pain · United States4CompletedKeenova TherapeuticsMar 201650
NCT02735122Post Operative Dental Pain · United States3CompletedJohnson & JohnsonOct 5, 2016420
NCT02746263Pain, Postoperative · United States4TerminatedKeenova TherapeuticsMay 5, 20161
NCT02689063Pain, Postoperative · United States3CompletedAFT PharmaceuticalsJun 30, 2017276
NCT02678416Pain · United States4CompletedKeenova TherapeuticsJun 13, 201679
NCT02678234Respiratory Tract Infections3WithdrawnGlaxoSmithKlineApr 1, 20170
NCT02730364Respiratory Tract Infections3WithdrawnGlaxoSmithKlineApr 1, 20170
NCT02654860Phase 1: Pain Management · Switzerland2Completedsintetica-saFeb 201969
NCT02641899Healthy · United States1CompletedIntarcia TherapeuticsMar 201633
NCT02583594Multiple Sclerosis, Chronic Progressive · Spain1CompletedSanofiMar 201624
NCT02422966Ductus Arteriosus, Patent · Italy2CompletedAngelini PharmaJan 2019110
NCT02320708Toothache · United States2CompletedJohnson & JohnsonApr 30, 2015240
NCT02311881Pain · United States3CompletedGlaxoSmithKlineFeb 2016960
NCT02183688Migraine Disorders3CompletedBoehringer IngelheimJan 20031,889
NCT01973205Migraine Disorders · United States3CompletedNovartisJul 2014900
NCT01960114Toothache · United States2CompletedJohnson & JohnsonApr 2014403
NCT01891435Fever · Qatar–CompletedHamad MedicalDec 2011434
NCT01842633Pain · United States3TerminatedGlaxoSmithKlineMar 31, 2015365
NCT01822665Gastrointestinal Mucosal Damage · United States4CompletedGlaxoSmithKlineJul 201228
NCT01814878Pain, Postoperative3CompletedJohnson & JohnsonJan 2011320
NCT01767428Fever1CompletedGlaxoSmithKlineApr 201030
NCT01728246Osteoarthritis · Philippines4CompletedJohnson & JohnsonMay 2008473
NCT01686646Common Cold · United Kingdom3CompletedGlaxoSmithKlineNov 2012240
NCT01635101Acute Pain · United States3CompletedKeenova TherapeuticsAug 2015197
NCT01592227Pain · United States1CompletedGlaxoSmithKlineDec 200930
NCT01568749Agnosia · United States1CompletedGlaxoSmithKlineAug 200914
NCT01551836Healthy Volunteer · United Kingdom1CompletedGlaxoSmithKlineJun 200912

How it is read

Names in the registry

  • “Acetaminophen”, 24 entries
  • “Paracetamol”, 10 entries
  • “IV Acetaminophen”, 10 entries
  • “Experimental paracetamol formulation”, 5 entries
  • “acetaminophen”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.